Equities

Vcanbio Cell & Gene Engineering Corp Ltd

600645:SHH

Vcanbio Cell & Gene Engineering Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)18.75
  • Today's Change-2.96 / -13.63%
  • Shares traded28.61m
  • 1 Year change-9.02%
  • Beta1.3143
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,5811,3811,190
Total Receivables, Net651624541
Total Inventory248248227
Prepaid expenses284467
Other current assets, total0.10125.89
Total current assets2,5082,3102,030
Property, plant & equipment, net721772776
Goodwill, net703703703
Intangibles, net147138149
Long term investments1,0351,0621,082
Note receivable - long term375266
Other long term assets111111
Total assets5,4115,2855,033
LIABILITIES
Accounts payable10310570
Accrued expenses148135139
Notes payable/short-term debt169.2817
Current portion long-term debt/capital leases302823
Other current liabilities, total1,1841,1951,147
Total current liabilities1,4821,4711,396
Total long term debt8610248
Total debt13213987
Deferred income tax233535
Minority interest1159869
Other liabilities, total222323
Total liabilities1,7271,7291,570
SHAREHOLDERS EQUITY
Common stock468468468
Additional paid-in capital3,3773,3843,383
Retained earnings (accumulated deficit)(294)(401)(514)
Treasury stock - common------
Unrealized gain (loss)8570149
Other equity, total4834(23)
Total equity3,6843,5563,463
Total liabilities & shareholders' equity5,4115,2855,033
Total common shares outstanding468468468
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.